Clinical trials: Tamoxifen
Alzheimer Disease
Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease
The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability…
- Trial name
- NCT00065767
- Testing
- Raloxifene
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Male Breast Cancer
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (MALE).
- Trial name
- MALE (NCT01638247)
- Testing
- Tamoxifen, Tamoxifen and GnRH analogue, Exemestane and GnRH analogue
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)
This controlled study is designed to evaluate the relapse-free survival of UFT + TAM compared with CMF + TAM. Patients are randomly assigned to receive either CMF + TAM or UFT + TAM within 6 weeks after surgery.
- Trial name
- NCT00152178
- Testing
- UFT (uracil, tegafur) and tamoxifen, CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen
- Where
- Japan
- Volunteers
- 680 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Bleeding, Implants
Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
The etonogestrel (ENG) subdermal contraceptive implant (ENG implant) is a highly effective method of preventing pregnancy, but it has bleeding side effects that make it unappealing for many women.
- Conditions
- Bleeding, Implants, Breakthrough Bleeding
- Trial name
- Tamoxifen/BTB (NCT02903121)
- Testing
- Tamoxifen, Tamoxifen (open label)
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Osteoporosis
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04736693
- Testing
- Raloxifene, Zoledronic Acid
- Where
- United States
- Volunteers
- 18,028 people
- Sponsor
- Brigham and Women's Hospital
Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the efficacy of palbociclib in combination with Endocrine therapy over Endocrine therapy alone…
- Trial name
- NCT03969121
- Testing
- Palbociclib, Endocrine therapy
- Where
- 25 sites in Australia, Hong Kong and 3 more
- Volunteers
- 141 people
- Sponsor
- Kyoto Breast Cancer Research Network
Breast Cancer
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
The investigators plan to examine endoxifen and 4-OH-Tam as a function of the tamoxifen dose in patients with a genetic CYP2D6 polymorphism.
- Trial name
- NCT00900744
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Vasomotor Symptoms, Endometrial Safety
Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen
This pilot study was designed to explore the effects of combined treatment with raloxifene HCl 60 mg and oral 17 beta-estradiol 1mg/day on the number of vasomotor episodes (hot flashes plus night sweats) in postmenopausal women…
- Trial name
- NCT00332553
- Testing
- Raloxifene, medroxyprogesterone acetate, estrogen
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
This randomized phase II trial studies how well temsirolimus with or without megestrol acetate and tamoxifen citrate works in treating patients with endometrial cancer that has spread to other places in the body and usually…
- Conditions
- Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer
- Trial name
- NCT00729586
- Testing
- Laboratory Biomarker Analysis, Megestrol Acetate, Tamoxifen Citrate
- Where
- 108 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00003418
- Testing
- exemestane, tamoxifen citrate
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 4,400 people
- Sponsor
- International Collaborative Cancer Group
Urinary Bladder Neoplasms
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
The major objective of this two-stage phase II study is to determine whether tamoxifen is deserving of further study in metastatic bladder cancer.
- Trial name
- NCT00710970
- Testing
- Tamoxifen
- Where
- 2 sites in United States, Italy
- Volunteers
- 28 people
- Sponsor
- Seth Lerner
Breast Cancer Recurrent
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
POLAR is a phase III clinical trial, which will test the safety and efficacy of an investigational combination of drugs to learn whether the combination of drugs works for a specific cancer.
- Trial name
- POLAR (NCT03820830)
- Testing
- Palbociclib 125mg, Standard endocrine therapy
- Where
- 53 sites in Austria, France and 4 more
- Volunteers
- 405 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer, Lymphoma
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the…
- Conditions
- Breast Cancer, Lymphoma, Hodgkin's Lymphoma
- Trial name
- NCT01788839
- Testing
- surveys, Blood draw, Transvaginal ultrasounds
- Where
- 7 sites in United States
- Volunteers
- 475 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostatic Intraepithelial Neoplasia
A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)
If you are a male 30 years of age or older and have a positive diagnosis of high grade (II or III) prostate Intraepithelial Neoplasia (PIN) or have had an abnormal/suspicious prostate biopsy, you may be eligible for this study.
- Trial name
- NCT00028353
- Testing
- GTX-006 (Acapodene)
- Where
- 25 sites in United States
- Volunteers
- 500 people
- Sponsor
- GTx
Breast Cancer
The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers
Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers
- Trial name
- OTT 17-01 (NCT03211572)
- Testing
- Tamoxifen
- Volunteers
- 82 people
- Sponsor
- Ottawa Hospital Research Institute
Metastatic Breast Cancer
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
Neutropenia is a common complication from dalpiciclib. Mecapegfilgramtim (code name HHPG-19K), a long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF), has been developed.
- Trial name
- NCT05463601
- Testing
- Mecapegfilgrastim, dalpiciclib, exemestane, fulvestrant, letrozole, tamoxifen
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cognition, Aging
Cognition in the Study of Tamoxifen and Raloxifene
The purpose of this study is to assess the effects of tamoxifen and raloxifene on cognitive aging in selected cognitively-healthy women.
- Trial name
- Co-STAR (NCT00687102)
- Testing
- tamoxifen, raloxifene
- Where
- 134 sites in United States, Canada
- Volunteers
- 1,498 people, healthy volunteers welcome
- Sponsor
- Wake Forest University
Osteoporosis, Postmenopausal
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).
- Trial name
- NCT00383422
- Testing
- Arzoxifene, Raloxifene
- Where
- 21 sites in United States, Argentina and 6 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Brain Tumor
Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
The study investigators are testing to see if patients receiving radiation treatment for brain cancer along with raloxifene plus memantidine take longer to develop memory issues.
- Trial name
- MemoryRT (NCT07470606)
- Testing
- Memantine, Raloxifene
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Breast Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative…
- Trial name
- ELEGANT (NCT06492616)
- Testing
- Elacestrant, Anastrozole, Letrozole
- Where
- 567 sites in United States, Argentina and 26 more
- Volunteers
- 4,220 people
- Sponsor
- Stemline Therapeutics, Inc.